Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Intas Biopharmaceuticals Ltd - (Amalgamated)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Intas Biopharmaceuti Share Price
BSE Share Price
Not Listed
Not Listed
Intas Biopharmaceuticals Ltd - (Amalgamated)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Intas Biopharmaceuti Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹0 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹0
TTM Sales
₹88.2 Cr.
Book Value per Share
-
P/E Ratio
0.00
Industry PE
53.5
Price to Book (P/B)
0.00
Price to Sales (P/S)
0.00
EV/EBITDA
0.00
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
1.90%
Return on Capital Employed (ROCE)
5.77%
Return on Assets (ROA)
1.04%
Operating Profit Margin
33.7%
Net Profit Margin
4.84%
Gross Profit Margin
23.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
9.12%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
74.93%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
402.35%
Asset Quality
Promoter Holding
%
Pledged shares (%) of Promoter's holding (%)
%
Reserves
₹339 Cr.
Equity
₹0 Cr.
Face Value
₹10
All Time Low / High
- / -
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -4.6% | 3% | 11.5% | 15.5% | 5.2% | 5.8% | - |
Growth Parameters ⓘ |
|||||||
| Sales ⓘ | 6.6 | 26.1 | 47.8 | 89.4 | 80.8 | 88.2 | 88 |
| Sales YoY Gr. | - | 296.5% | 83.1% | 87.1% | -9.6% | 9.1% | - |
| Adj EPS ⓘ | -768.4 | -7.8 | 57.2 | 62.1 | 3.9 | 5.4 | 0 |
| YoY Gr. | - | NA | NA | 8.5% | -93.8% | 39.4% | - |
| BVPS (₹) ⓘ | 4,167 | 110.7 | 307.2 | 333.3 | 335.9 | 438 | 0 |
| Adj Net Profit ⓘ | -3.8 | -1.5 | 11 | 18.9 | 1.2 | 4.3 | 0 |
| Cash Flow from Ops. ⓘ | 1 | 4.5 | 8.9 | 12 | 6.4 | -83.7 | - |
| Debt/CF from Ops. ⓘ | 29.4 | 13.9 | 7.6 | 8.5 | 27.3 | -1.1 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 68.1% | 22.7% | 9.1% | ||||
| Adj EPS ⓘ | NA | NA | -54.5% | 39.4% | ||||
| BVPSⓘ | NA | -36.3% | 12.6% | 30.4% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -16.9 | -6.8 | 23.5 | 20.2 | 1 | 1.8 | 0 |
| Op. Profit Mgn % ⓘ | -19.5 | 19.1 | 34.4 | 34.5 | 21.6 | 33.7 | NAN |
| Net Profit Mgn % ⓘ | -58.4 | -5.7 | 22.9 | 21.2 | 1.5 | 4.8 | 0 |
| Debt to Equity ⓘ | 1.4 | 2.9 | 0.9 | 0.9 | 1.5 | 0.3 | - |
| Working Cap Days ⓘ | 0 | 141 | 146 | 154 | 281 | 518 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 16 | 12 | 41 | 112 | 74 | 0 |
Valuation of Intas Biopharmaceuti - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
No Data To Display
Promoter's Holding & Share Pledging
Financials
| PARTICULARS | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 |
|---|---|---|---|---|---|---|
| Sales | 6.58 | 26.09 | 47.77 | 89.38 | 80.83 | 88.20 |
| Operating Expenses ⓘ + | 7.88 | 21.15 | 31.36 | 58.96 | 63.84 | 58.47 |
| Operating Profit ⓘ | -1.29 | 4.94 | 16.41 | 30.42 | 16.99 | 29.72 |
| Operating Profit Margin (%) | -19.7% | 18.9% | 34.3% | 34.0% | 21.0% | 33.7% |
| Other Income ⓘ + | 0.09 | 0.07 | 0.88 | 2.34 | 2.85 | 0.79 |
| Interest ⓘ | 0.76 | 1.76 | 3.31 | 4.88 | 10.05 | 9.41 |
| Depreciation ⓘ | 1.20 | 2.98 | 4.42 | 5.07 | 6.69 | 9.40 |
| Profit Before Tax ⓘ | -3.16 | 0.27 | 9.55 | 22.81 | 3.10 | 11.70 |
| Tax ⓘ | 0.69 | 1.78 | -1.43 | 4.20 | 2.24 | 7.43 |
| Profit After Tax | -3.85 | -1.52 | 10.98 | 18.61 | 0.85 | 4.27 |
| PAT Margin (%) | -58.5% | -5.8% | 23.0% | 20.8% | 1.1% | 4.8% |
| Adjusted EPS (₹) | -769.0 | -7.9 | 57.3 | 61.0 | 2.8 | 5.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0.80% | 0% | 0% |
| PARTICULARS | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 20.83 | 21.18 | 72.16 | 114.88 | 115.68 | 347.13 | |||||
| Debt + | 29.16 | 62.13 | 68.18 | 101.60 | 175.12 | 90.62 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Trade Payables | 3.59 | 8.70 | 9.60 | 13.76 | 22.03 | 11.45 | |||||
| Others Liabilities ⓘ | 12.83 | 14.95 | 14.88 | 22.38 | 29.68 | 30.24 | |||||
| Total Liabilities ⓘ | 66.41 | 106.97 | 164.82 | 252.62 | 342.50 | 479.43 | |||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 41.21 | 55.59 | 63.02 | 88.64 | 96.65 | 126.68 | |||||
| CWIP ⓘ | 17.10 | 32.83 | 67.68 | 97.71 | 155.76 | 149.93 | |||||
| Investments ⓘ | 1.21 | 3.99 | 6.28 | 12.96 | 12.96 | 24.45 | |||||
| Inventories | 2.15 | 6.27 | 11.35 | 13.85 | 22.61 | 20.25 | |||||
| Trade Receivables | 2.65 | 5.67 | 5.52 | 23.23 | 32.39 | 12.20 | |||||
| Cash Equivalents | 0.21 | 0.65 | 3.64 | 2.15 | 3.63 | 1.43 | |||||
| Others Assets ⓘ | 1.88 | 1.98 | 7.34 | 14.07 | 18.50 | 144.49 | |||||
| Total Assets ⓘ | 66.41 | 106.97 | 164.82 | 252.62 | 342.50 | 479.43 | |||||
| PARTICULARS | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0.99 | 4.48 | 8.94 | 11.97 | 6.41 | -83.65 |
| Cash Flow From Investing Activity ⓘ + | -9.63 | -35.32 | -48.87 | -66.32 | -71.80 | -44.73 |
| Cash Flow From Financing Activity ⓘ + | 8.56 | 31.28 | 42.74 | 52.87 | 66.87 | 126.18 |
| Net Cash Flow ⓘ | -0.09 | 0.44 | 2.81 | -1.49 | 1.48 | -2.21 |
| PARTICULARS | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -18.47 | -7.21 | 27.46 | 23.21 | 0.84 | 1.9 | ||||
| ROCE (%) | -4.62 | 3 | 11.5 | 15.52 | 5.15 | 5.77 | ||||
| Asset Turnover Ratio | 0.1 | 0.31 | 0.35 | 0.43 | 0.27 | 0.21 | ||||
| PAT to CFO Conversion(x) | N/A | N/A | 0.81 | 0.64 | 7.54 | -19.59 | ||||
| Working Capital Days | ||||||||||
| Receivable Days | 139 | 57.20 | 42.70 | 58.70 | 125.60 | 92.30 | ||||
| Inventory Days | 112.60 | 57.80 | 67.30 | 51.50 | 82.30 | 88.70 | ||||
| Payable Days | 551 | 319.30 | 405.70 | 180.70 | 281.20 | 312.50 | ||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Intas Biopharmaceuticals Ltd - (Amalgamated) FAQs
The current trading price of Intas Biopharmaceuti on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Intas Biopharmaceuti stood at ₹0.00 Cr
The latest P/E ratio of Intas Biopharmaceuti as of 31-Dec-1969 is 0.00.
The latest P/B ratio of Intas Biopharmaceuti as of 31-Dec-1969 is 0.00.
The 52-week high of Intas Biopharmaceuti is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Intas Biopharmaceuti is ₹88.20 ( Cr.) .
Data is not available for this company.
No data found
No data found
About Intas Biopharmaceuticals Ltd - (Amalgamated)
No data to display
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
